Health & Biotech
Opthea’s 100pc jump was great, but only scratched the surface, says CEO Megan Baldwin
Health: Immuron takes a dive after drug fails in alcoholic hepatitis trial
Check-up: Opthea’s one-day gain has them leading the health pack
MGC Pharma is about to start selling into China
Health: Opthea’s anti-macular degeneration drug passes Phase IIb trial, shares double
Why ResMed’s CFO chose Osteopore as his first chairman opportunity
Health: PainChek expands into Singapore with landmark deal
Creso just locked in a New Zealand distribution deal for its CBD products
Dr Boreham’s Crucible: Regeneus has pain sorted; now for long-term gain
Finders, keepers: Big pharma’s losses can be a small cap biotech’s gain
Creso receives first order of its cannaQIX 50 pain relief lozenges from Burleigh Heads
Analysts are suddenly bullish on ResApp ahead of a ‘critical’ six months
Quarterlies: The five 4C filings investors liked most in health today
Will Novita’s Victorian deal be the step-change it needs?
Health: Another day, another Medibio client win; it’s now up 166pc in a month
MGC Pharma prepping follow-up studies after brain cancer results
Health: Corporate wellness stock Medibio’s latest partnership sends it up 24pc
Featured Health & Biotech Stocks
Health & Biotech
Healthcare stocks are as varied as the solutions they are working to solve. The sector covers biotech stocks developing breakthrough pharmaceutical drugs and vaccines to medtech companies launching the latest and greatest medical devices they hope will change the face of healthcare.
Even the ‘budding’ medical cannabis industry is in the mix as researchers explore new applications and treatments.
If you want to know what’s happening with emerging health stocks on the ASX, Stockhead has you covered, with daily stock news, expert insight and research. You can also recap broader industry trends and recent share price movements across the sector in our regular ‘Check Up’ feature.
Accurate, up-to-date news stories are important, especially in the health sector where progress is often slow and risk often high. That’s why we’re focused on helping small cap investors make sense of the medical jargon.
